In a landmark finding presented at the European Society of Cardiology Congress 2026, Novo Nordisk has announced that semaglutide — the active ingredient in Ozempic and Wegovy — demonstrated a statistically significant 22% reduction in major adverse cardiovascular events (MACE) among patients with overweight or obesity who did not have diabetes. The SELECT trial enrolled 17,604 patients across 804 sites in 41 countries, making it one of the largest cardiovascular outcome trials ever conducted in this population.
The primary composite endpoint — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — was reached by 6.5% of patients in the semaglutide group compared to 8.0% in the placebo group over a median follow-up of 39.8 months. The absolute risk reduction of 1.5 percentage points translates to a number needed to treat of 67 patients to prevent one MACE over approximately 3.3 years.
Mechanism Beyond Weight Loss
Notably, the cardiovascular benefit appeared to emerge within the first 6 months of treatment, before substantial weight loss had occurred, suggesting that the cardioprotective effects of GLP-1 receptor agonism may be at least partially independent of weight reduction. Investigators hypothesize that direct cardiac effects — including reduced inflammation, improved endothelial function, and favorable changes in cardiac metabolism — contribute meaningfully to the observed benefit.
"This trial fundamentally changes how we think about obesity pharmacotherapy. We are no longer just treating a metabolic condition — we are reducing cardiovascular risk in a population that has historically been undertreated by cardiologists."
The findings are particularly significant because the enrolled population had no history of diabetes, distinguishing SELECT from earlier cardiovascular outcome trials of GLP-1 agents such as LEADER (liraglutide) and SUSTAIN-6 (semaglutide), which enrolled exclusively diabetic patients. This expands the potential treatment-eligible population by an estimated 120 million adults in the United States alone.
Regulatory and Clinical Implications
Novo Nordisk has filed supplemental New Drug Applications with both the FDA and EMA seeking a cardiovascular risk reduction indication for semaglutide 2.4 mg weekly injection. The FDA has granted Priority Review with a PDUFA date of November 14, 2026. If approved, this would represent the first obesity medication to carry a cardiovascular outcomes label — a development that could dramatically expand insurance coverage and reimbursement.
Cardiologists interviewed by Biotechnology Media Insights expressed enthusiasm tempered by practical concerns. "The data are compelling, but the cost-effectiveness analyses will need to demonstrate value at current pricing levels before payers agree to broad coverage," noted Dr. Jennifer Walsh, a preventive cardiologist at Massachusetts General Hospital. "At $1,350 per month, even a 22% MACE reduction may not clear the threshold for routine use without meaningful price reductions."
Competitive Landscape
The SELECT results intensify competitive pressure on Eli Lilly, whose tirzepatide (Mounjaro/Zepbound) — a dual GIP/GLP-1 agonist — has demonstrated superior weight loss versus semaglutide in head-to-head trials but lacks cardiovascular outcomes data. Lilly's SURMOUNT-MMO cardiovascular outcomes trial is expected to report results in late 2027. Analysts estimate that a positive cardiovascular label for semaglutide could accelerate market penetration, with consensus forecasts now projecting peak Wegovy revenues exceeding $22 billion annually by 2030.
SELECT trial design overview: 17,604 patients enrolled across 41 countries with median follow-up of 39.8 months. Source: NEJM 2026.
The SELECT trial also reported favorable secondary outcomes, including a 19% reduction in heart failure hospitalizations and a 10% reduction in all-cause mortality, though the latter did not reach statistical significance. Adverse events were consistent with the established safety profile of semaglutide, with gastrointestinal events — nausea (44%), diarrhea (30%), vomiting (24%) — being the most common reasons for treatment discontinuation.
About the Author
Dr. Sarah Chen
Senior Editor, Clinical Development
Dr. Chen has covered cardiovascular and metabolic disease for Biotechnology Media Insights since 2021. She holds a PhD in Pharmacology from Johns Hopkins University and previously worked as a medical affairs director at Boehringer Ingelheim.
